All In Biotech

Drug Trial Radar · NCT05581719

A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

14

Actual

Start

Nov 15, 2022

Primary completion

Apr 15, 2024

Study completion Apr 15, 2024

Sponsor

Lead sponsor
Enlivex Therapeutics RDO Ltd.Industry
Sponsor type
Industry
First posted
Oct 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, non-randomized, multicenter, Phase 1/2a study to evaluate the safety and potential efficacy of Allocetra-OTS in the treatment of advanced solid tumor malignancy as monotherapy or in combination with an anti-PD-1 therapy.

Conditions

  • Solid Tumor
  • Peritoneal Metastases
  • Peritoneal Cancer

Interventions

  • Allocetra-OTSDrug

    Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.

  • NivolumabDrug

    Immune checkpoint inhibitor (anti-PD-1 antibody)

  • TislelizumabDrug

    Immune checkpoint inhibitor (anti-PD-1 antibody)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Allocetra-OTSTime frame: 3-5 weeks

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Rambam Medical Center

    Haifa, Israel

  • Hadassah Medical Center

    Jerusalem, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • Clínica Universidad de Navarra

    Madrid, Spain

  • NEXT Madrid

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.